Introduction
============

Two recent reviews have described the relative outcomes of endovascular repair (EVAR) versus open surgical repair (OSR) ([@b36-vhrm-4-1011]; [@b54-vhrm-4-1011]) and of EVAR alone ([@b44-vhrm-4-1011]) for abdominal aortic aneurysms (AAA) based on evidence from both randomized control trials (RCTs) and nonrandomized control trials (nRCTs). Despite these recent reviews, there are limitations in the accumulated evidence for an assessment comparing EVAR and OSR. As the authors suggest, the major differences between the RCTs and the nRCTs relate to differences in baseline characteristics of the patient populations and overall study design. While the recent reviews have cautioned the interpretation of the differential outcomes of EVAR versus OSR found in RCT compared to nRCTs, they do not assess the degree to which the imbalances or different study design impact relative outcomes.

For example, patients in RCTs tend to have lower ASA risk levels than patients in nRCTs, and the average ASA risk tends to be higher for EVAR than OSR patients in nRCTs ([@b88-vhrm-4-1011]). This baseline imbalance for AAA repair has continued ever since EVAR was first introduced to benefit patients with AAA who were physiologically at high risk for OSR or who were anatomically suitable for EVAR ([@b80-vhrm-4-1011]). Despite the focus on high risk patients, the benefits of EVAR in lower risk patients has also recently been established in two large RCTs, DREAM ([@b83-vhrm-4-1011]) and EVAR-1 ([@b51-vhrm-4-1011]). Despite these two landmark trials, only one small RCT has been completed to assess differences in quality of life between EVAR and OSR patients ([@b92-vhrm-4-1011]). In order to compare and contrast the outcome evidence of EVAR and OSR in RCTs and nRCTs, differences in patient baseline risk levels and the degree to which these risk levels differ between EVAR and OSR in observational studies need to be investigated.

A major limitation of the recent reviews is the inclusion of studies that should have otherwise been excluded. For example, some studies are multi-center in nature and the meta-analysis includes the results of the multi-center studies and the redundant constituent single center evidence ([@b18-vhrm-4-1011]; [@b91-vhrm-4-1011]; [@b67-vhrm-4-1011]; [@b70-vhrm-4-1011]). This is particularly evident with the large device trials, the Lifeline Registry ([@b64-vhrm-4-1011]) and the Eurostar Registry ([@b20-vhrm-4-1011]). In addition, other evidence that should be excluded is the studies that include early evidence from the Ancure multi-center trial, even though the device was temporarily removed from the market for underreporting complications ([@b75-vhrm-4-1011]).

Interestingly, EVAR was originally intended for high risk patients, but there has been little cumulative evidence reported for high risk patients only ([@b88-vhrm-4-1011]). To address the benefits to high risk patients only, a review of studies where both EVAR and OSR patients are deemed at high medical risk should be the starting point. Similarly, EVAR is usually offered to anatomically suitable candidates. Yet, no review has isolated studies where both EVAR and OSR patients are anatomically suitable for EVAR. To include anatomically suitable patients for a comparative review would eliminate a significant bias in terms of the effects of vasculature on surgical outcomes ([@b102-vhrm-4-1011]).

A further bias is added in reviews if the authors do not incorporate inclusion criterion based on treatment volumes or control for treatment volume in the analysis. This is important because most centers have low annual volume and treatment volumes have been shown to be related to treatment outcomes for endovascular repair ([@b19-vhrm-4-1011]) as well as other cardiac procedures ([@b44-vhrm-4-1011]). Accordingly, it is important to compare relative outcomes for EVAR and OSR adjusting for different treatment volumes.

Finally, EVAR technology has been evolving over time due to new device generations and improvements in surgical techniques such as crossover grafts ([@b74-vhrm-4-1011]). The recent review of EVAR alone studies described a decreasing rate of mortality over time ([@b44-vhrm-4-1011]). Reviews that ignore the potential impact of time trends on the relative rate of mortality or systemic events of EVAR over time may potentially introduce bias.

The objectives of this systematic literature review were to address issues left unanswered by earlier reviews, such as: 1) to describe and compare the patient characteristics from the identified observational and randomized controlled trials of EVAR and OSR patients; 2) to examine differences in outcome measures between the treatment groups by study design and characteristics; and 3) to evaluate relative trends in mortality and endoleak rates over time. More specifically, this report investigated the effects of baseline characteristics imbalance, study design (ie, nRCT versus RCT), center status (ie, multi-center versus single center), patient risk status, EVAR suitability, treatment volume (ie, low versus high), and year of study publication on patient outcomes.

Methods
=======

Literature search
-----------------

Literature search strategies were developed to identify papers comparing EVAR to OSR. Strategies for each of the following databases were developed and performed individually in OVID's: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Health and Psychosocial Instruments (HAPI), and Evidence-Based Medicine (EBM) Reviews (including Cochrane Database of Systematic Reviews (CDSR), ACP Journal Club, Database of Abstracts of Reviews of Effects (DARE) and Cochrane Central Register of Controlled Trials (CCTR)). Results were limited to human and English language studies published between 1990 and November 2006 inclusive. Identification of duplicate citations was completed using Reference Manager (v.10; Thomson ResearchSoft, Philadelphia, PA, USA). RCTs, controlled clinical trials, comparative observational studies, case series studies, and population-based registries assessing the efficacy and/or safety of EVAR versus OSR were all included in the review.

Titles and abstracts (when available) of all search results were screened using predefined criteria in order to identify publications that discussed the use of EVAR and OSR for the management of AAA. When it could not be determined from the information available whether an item met the inclusion criteria or not, the article was reviewed in full-text.

Inclusion criteria included nonruptured AAA repair, of at least a mean AAA diameter of greater than 5 cm, and a publication date from 1990 onwards. Citations were excluded if they reported a mixed patient population including patients with thoracic-abdominal aneurysms, iliac aneurysms, ruptured or infected aorta, emergency aortic repair. No restriction based on clinical study design was used and nonrandomized trials and patient registries were included. All relevant or potentially relevant studies were then retrieved in full-text.

Review of full-text articles was conducted to identify publications with unique patient data using preset criteria. Also, clinical studies regarding the FDA-approved clinical trials related to the Ancure device (Guidant) were identified and excluded from further analysis due to the potential under-reporting of device related complications ([@b17-vhrm-4-1011]).

Data extraction
---------------

For unique comparative clinical studies, data were abstracted using a standard form to record details of the study design and methods, patient baseline characteristics, technical aspects of EVAR and OSR and outcome measures of interest according to SVS reporting standards ([@b26-vhrm-4-1011]).

Clinical outcomes were obtained from studies which described 30 day and post 30 day events. When longer term cumulative evidence was available (\>30 days), 30 day events were not included in the analysis of the long term outcome data. Studies were classified as multi-center or single center. Where studies examined outcomes from a single center over a period of time greater than one year, annual treatment volume was estimated by dividing the number of patients in the study by the enrollment duration in years. Further, after determining the median surgical volume of institutions performing EVAR, surgical volume was divided into two categories: low volume institutions (identified as having, on average, less than 30 patients per year) and high volume institutions (completed 30 or more procedures per year).

Studies including only high-risk surgical patients were also identified. High-risk patients were classified as high-risk if any one of the following characteristics was present: age \>80, ASA III or IV, or an existing systemic complication (cardiac, pulmonary, renal) ([@b55-vhrm-4-1011]) If available, further information was extracted from the studies regarding the suitability of patients who received OSR as to whether they could have received EVAR.

Statistical analysis
--------------------

Statistical analysis was carried out using Excel 2002 (Microsoft Corp., Redmond, WA, USA) and Stata (StataCorp., College Station, TX, USA) with comparison of dichotomous outcomes expressed as odds ratios (OR). An OR less than 1 indicated a lower rate in EVAR than OSR. Continuous variables were analyzed using weighted mean differences (WMD). A WMD less than zero indicated a lower rate in EVAR than OSR. A level of significance (α) of 0.05 was used to indicate statistical significance.

Meta-regression analyses (including a random effect) were performed using Stata *metareg* command to test if there were differences in outcomes between EVAR and OSR with respect to study enrolment time. Where there were multi-year enrolment periods, the middle of the time period was used as the independent variable. Trends in comparative outcomes which were analyzed and included were operative mortality, systemic and vascular complications, and adjuvant procedures. Trends in EVAR specific outcomes such as the rate of endoleaks (I--IV) and conversion were also investigated. A level of significance (α) of 0.05 was used to indicate statistical significance in the trend coefficient.

Results
=======

Literature search
-----------------

The literature search initially completed on 20 May 2005 and updated on 28 Nov 2006 identified a combined total of 3,946 unique citations (see [Figure 1](#f1-vhrm-4-1011){ref-type="fig"}). The following evaluation is based on 84 comparative studies, containing unique patient data comparing EVAR to OSR.

Study characteristics
---------------------

These 84 studies included 4 randomized controlled trials of which all 4 reported short-term outcomes ([@b30-vhrm-4-1011]; [@b51-vhrm-4-1011]; [@b83-vhrm-4-1011]; [@b92-vhrm-4-1011]) and 2 reported subsequent long-term outcomes ([@b15-vhrm-4-1011]; [@b50-vhrm-4-1011]). The other 78 comparative studies were observational evaluations (nRCT) (3 long term only) ([@b13-vhrm-4-1011]; [@b61-vhrm-4-1011]; [@b65-vhrm-4-1011]).

Overall, the identified studies contained data pertaining to 59,188 patients. In the 75 observational studies with perioperative outcomes reported (initial 30 days), there were 16,407 and 41,238 patients receiving EVAR and OSR, respectively. Of these observational studies, 16 were categorized as multi-center ([@b104-vhrm-4-1011]; [@b10-vhrm-4-1011]; [@b29-vhrm-4-1011]; [@b70-vhrm-4-1011]; [@b3-vhrm-4-1011]; [@b4-vhrm-4-1011]; [@b24-vhrm-4-1011]; [@b49-vhrm-4-1011]; [@b43-vhrm-4-1011]; [@b56-vhrm-4-1011]; [@b62-vhrm-4-1011]; [@b65-vhrm-4-1011]; [@b19-vhrm-4-1011]; [@b73-vhrm-4-1011]; [@b86-vhrm-4-1011]; [@b99-vhrm-4-1011]). The other 59 papers were single center evaluations subdivided based on annual surgical volume of 30 cases per year, identified 31 low volume centers ([@b33-vhrm-4-1011]; [@b60-vhrm-4-1011]; [@b90-vhrm-4-1011]; [@b95-vhrm-4-1011]; [@b9-vhrm-4-1011]; [@b28-vhrm-4-1011]; [@b68-vhrm-4-1011]; [@b87-vhrm-4-1011]; [@b11-vhrm-4-1011]; [@b31-vhrm-4-1011]; [@b41-vhrm-4-1011]; [@b66-vhrm-4-1011]; [@b97-vhrm-4-1011]; [@b47-vhrm-4-1011]; [@b52-vhrm-4-1011]; [@b81-vhrm-4-1011]; [@b94-vhrm-4-1011]; [@b96-vhrm-4-1011]; [@b7-vhrm-4-1011]; [@b46-vhrm-4-1011]; [@b105-vhrm-4-1011]; [@b1-vhrm-4-1011]; [@b16-vhrm-4-1011]; [@b48-vhrm-4-1011]; [@b53-vhrm-4-1011]; [@b57-vhrm-4-1011]; [@b84-vhrm-4-1011]; [@b32-vhrm-4-1011]; [@b69-vhrm-4-1011]; [@b98-vhrm-4-1011]; [@b79-vhrm-4-1011]), and 28 high volume centers ([@b8-vhrm-4-1011]; [@b38-vhrm-4-1011]; [@b25-vhrm-4-1011]; [@b89-vhrm-4-1011]; [@b27-vhrm-4-1011]; [@b45-vhrm-4-1011]; [@b77-vhrm-4-1011]; [@b12-vhrm-4-1011]; [@b71-vhrm-4-1011]; [@b85-vhrm-4-1011]; [@b103-vhrm-4-1011]; [@b23-vhrm-4-1011]; [@b93-vhrm-4-1011]; [@b6-vhrm-4-1011]; [@b34-vhrm-4-1011]; [@b35-vhrm-4-1011]; [@b37-vhrm-4-1011]; [@b58-vhrm-4-1011]; [@b59-vhrm-4-1011]; [@b2-vhrm-4-1011]; [@b5-vhrm-4-1011]; [@b21-vhrm-4-1011]; [@b39-vhrm-4-1011]; [@b82-vhrm-4-1011]; [@b101-vhrm-4-1011]; [@b72-vhrm-4-1011]; [@b40-vhrm-4-1011]; [@b78-vhrm-4-1011]).

Five studies included information regarding patients that were surgically suitable for either procedure ([@b9-vhrm-4-1011]; [@b41-vhrm-4-1011]; [@b35-vhrm-4-1011]; [@b47-vhrm-4-1011]; [@b46-vhrm-4-1011]), 8 studies specifically examined the efficacy of high-risk patients only ([@b38-vhrm-4-1011]; [@b23-vhrm-4-1011]; [@b41-vhrm-4-1011]; [@b81-vhrm-4-1011]; [@b57-vhrm-4-1011]; [@b73-vhrm-4-1011]; [@b32-vhrm-4-1011]; [@b79-vhrm-4-1011]) Long-term outcomes (\>30 days) were reported in 25 observational studies with long term comparative outcomes of up to 3 years mean follow-up ([@b104-vhrm-4-1011]; [@b9-vhrm-4-1011]; [@b13-vhrm-4-1011]; [@b28-vhrm-4-1011]; [@b10-vhrm-4-1011]; [@b71-vhrm-4-1011]; [@b87-vhrm-4-1011]; [@b23-vhrm-4-1011]; [@b6-vhrm-4-1011]; [@b29-vhrm-4-1011]; [@b35-vhrm-4-1011]; [@b61-vhrm-4-1011]; [@b94-vhrm-4-1011]; [@b7-vhrm-4-1011]; [@b21-vhrm-4-1011]; [@b39-vhrm-4-1011]; [@b46-vhrm-4-1011]; [@b49-vhrm-4-1011]; [@b105-vhrm-4-1011]; [@b48-vhrm-4-1011]; [@b65-vhrm-4-1011]; [@b73-vhrm-4-1011]; [@b19-vhrm-4-1011]; [@b22-vhrm-4-1011]; [@b79-vhrm-4-1011]).

Differences between the EVAR and OSR treatment groups for various baseline characteristics and estimates of short-term mortality, systemic complications, procedural outcomes, local/vascular complications, and EVAR specific outcomes are described below.

Differences between patient characteristics and relative outcomes are discussed in the following order: RCTs versus observational studies, multi-center versus single center observational studies, studies that have patients that are suitable for both procedures (EVAR and OSR), studies with only high risk patients, and finally high volume versus low volume single center evidence.

Patient characteristics
-----------------------

### RCT vs observational studies

As shown in [Table 1](#t1-vhrm-4-1011){ref-type="table"}, patients enrolled in the EVAR and OSR arms of the 4 RCTs identified in this review had similar baseline characteristics except for pulmonary history (OR = 1.81, P \< 0.05). In contrast, in nonrandomized studies, patients receiving EVAR were more likely to be male (OR 1.64), have higher ASA III and IV ratings (OR 1.33, 1.49, respectively), and less likely to be ASA I or II (OR 0.20, 0.72). In all observational studies, EVAR patients had a higher surgical risk with greater baseline comorbidities than in OSR patients.

### Multi-center vs single center observational studies

In single or multi-center institutions, patients receiving EVAR were more likely than patients receiving OSR to have comorbidities such as smoking history, diabetes, hyperlipidemia, cardiac disease, and peripheral vascular disease (PVD) and less likely to have hypertension ([Table 1](#t1-vhrm-4-1011){ref-type="table"}). No statistical difference existed for AAA diameter and age for multi-center or single center evidence. Within the single center evidence, more patients had higher level of ASA in EVAR than OSR (ASA I to IV: OR 0.20, 0.72, 1.33, 2.38). In patients that received EVAR, there were more males, a greater number of individuals with a smoking history, more patients with diabetes, cardiac disease, peripheral vascular disease, and less hypertension. Multi-center evidence included less patients receiving EVAR that have cardiovascular disease, pulmonary, or renal disease, while single center evidence reported the opposite. Fewer patients had stroke in EVAR in multi-center studies, and more had hyperlipidemia in EVAR in single center studies.

### Studies with patients anatomically suitable for both EVAR and OSR

Only 5 studies stated that both EVAR and OSR patients were anatomically suitable for EVAR. While no statistical differences were found between AAA diameter and age, there was a much higher rate of ASA III and IV (OR 2.93, 12.34, respectively) in the EVAR patients than in the OSR patients as compared to the other study designs.

### Studies with only high risk patients

When examining the baseline characteristics of the 8 studies that had high risk patients only, there were no statistical baseline difference in AAA diameter and age. As observed with EVAR studies reporting patient suitability, there were statistically significantly more ASA IV patients that received EVAR than in all nRCTs (OR 10.80).

### High volume vs. low volume centers

The differences in baseline characteristics between the EVAR and OSR patients were still apparent when the single center studies are stratified based on their estimated procedural volume ([Table 1](#t1-vhrm-4-1011){ref-type="table"}). In institutions with high volume, patients receiving EVAR were also more likely than patients receiving OSR to have comorbidities such as smoking history, diabetes, hyperlipidemia, cardiac disease, and peripheral vascular disease (PVD) and less likely to have hypertension ([Table 1](#t1-vhrm-4-1011){ref-type="table"}).

Comparison of perioperative mortality and complications
-------------------------------------------------------

### RCT vs. observational studies

In the 75 nRCT studies, lower 30-day mortality existed in EVAR than OSR. The mortality difference reported in the nRCTs and in the RCTs was OR = 0.429 and 0.336, respectively ([Table 2](#t2-vhrm-4-1011){ref-type="table"}). Of all of the possible study designs and patient populations, RCTs reported the lowest OR for mortality (0.336). Within the published RCTs, there were no statistical differences between EVAR and OSR with respect to the occurrence of a MI, CHF, or arrhythmia, however, not all clinical outcomes were reported in the published papers ([Table 2](#t2-vhrm-4-1011){ref-type="table"}). In all designs lower rates of systemic complications were reported for all measures in EVAR treated patients compared to the OSR group, with the exception of limb ischemia which was higher in EVAR (OR 1.866).

### Multi-center vs single center observational studies

Similar mortality results existed in multi-center versus single center evidence. In addition, the OR of all complications for both multi-center and single center studies were less than 1, indicating the benefit of EVAR vs OSR, in terms of all systemic complications (cardiac, pulmonary, renal, stroke, and ischemia). In general, the multi-center studies reported lower OR for EVAR vs OSR for cardiac and renal complications, similar OR for pulmonary complications. The evidence for stroke and ischemia was mixed.

### Studies with patients anatomically suitable for both EVAR and OSR

No statistical difference between EVAR and OSR existed in mortality in anatomically suitable patients. This is important considering that the difference between EVAR and OSR baseline characteristics was the highest in this patient population. There was insufficient evidence to compare systemic complications.

### Studies with only high risk patients

No statistical difference existed in mortality in high-risk patients, despite ASA IV patients being 10.80 times more likely to receive EVAR than OSR. Similarly, there were less complications in EVAR than OSR for cardiac (OR 0.076) and pulmonary complications (OR 0.075) ([Table 2](#t2-vhrm-4-1011){ref-type="table"}).

### High volume vs. low volume centers

Similar differences in mortality existed in high volume versus low volume centers, when compared to all observational studies. In addition, there appeared to be little difference in systemic complications between high volume and low volume centers. This is despite high volume centers having a higher level of ASA IV patients, while low volume centers reported higher levels of other comomorbidities with the exception of pulmonary disease.

Surgical outcomes and local/vascular complications
--------------------------------------------------

Across all types of studies, and treatment volume risk status, surgical outcomes were better for EVAR in terms of OR time, blood loss, ICU length of stay (LOS), and total hospital, but these differences were not always statistically significant ([Table 3](#t3-vhrm-4-1011){ref-type="table"},[4](#t4-vhrm-4-1011){ref-type="table"}).

EVAR-specific outcomes
----------------------

A meta-analysis of the studies reporting endoleak data is presented in [Table 5](#t5-vhrm-4-1011){ref-type="table"}.

### Endoleaks

The rate of type 1 endoleaks was similar across study designs and patient populations, but was absent in the RCTs and highest in the suitable patient group. In contrast, the rate of type 2 endoleaks was lowest in the suitable patient group and in the RCTs.Type 3 and type 4 endoleaks, conversion, graft kinks, or folds are rare.

The rate of graft obstruction is high in the suitable patient group, and the rate of graft migration was highest in the high risk group.

Trends in endoleaks and ischemia over time
------------------------------------------

Examining the reported rate against the mid recruitment time of the study demonstrates that Type 1 endoleaks have been decreasing over time ([Table 6](#t6-vhrm-4-1011){ref-type="table"}). In comparison, the rate of type 2 endoleaks is relatively constant. Based on the study reports there has been a statistical increase in the rate of type 3 endoleaks over time (but this is the result of one outlier), and a decrease in the rate of type 4 endoleaks. Finally, the difference in the rate of limb ischemia has been decreasing over time (P \< 0.01).

In addition, when the trends in the difference in perioperative mortality were determined against the mid-enrolment time of the study, there was a small but statistically significant difference that persisted over time. The mortality difference has been changing at a rate of 0.066% per year (P \< 0.001).

Mid-term mortality
------------------

No statistical difference in mid-term mortality was found between EVAR and OSR over time. This evidence was based on a total of 6,289 patients with EVAR and 3,547 who received OSR and were followed in comparative nRCT up to a maximum of 36 months. In RCTs, 914 patients received EVAR, and 784 patients received OSR with a mean follow-up of 28 months of follow-up (table not provided).

Discussion
==========

In the question of EVAR versus OSR, the RCT evidence is limited. The enrolment period for DREAM was November 2000 to December 2003, and for EVAR 1 enrolment periods were September 1999 to December 2003. Based on this work and earlier work ([@b44-vhrm-4-1011]), this RCT evidence may be dated. Future evidence may come from an ongoing large multi-center trial, The Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms, which had an enrolment period, beginning in 2001 and ending in 2010. The recruitment period will be more up-to-date and thus, based on the results from this analysis, we should expect lower perioperative mortality rates in both EVAR and OSR, but similar mortality differences, as well as lower rates of endoleaks and ischemia. In the absence of more RCTs, observational data may provide the only current evidence.

There are some differences in evidence in nRCTs and RCTs. There are baseline imbalances that exist in nRCTs. In nRCTS, lower rates of outcomes are reported for all measures except limb ischemia which is higher in EVAR. A recent report has identified that there are only small differences between one large registry (Eurostar) and one large RCT (DREAM) ([@b63-vhrm-4-1011]).

There are a number of large multi-center studies, including the Eurostar registry, Lifeline Registry for post device trial outcomes, and the large multi-center device trials. Also present are state, veteran affairs, and US national registries. In this study, care was taken to exclude the single center studies that make up the device trial evidence. There are some baseline differences between the multi-center and single center evidence. However, outcomes are mostly similar; the exceptions being that endoleaks (type 1 and type 2 endoleaks) are reportedly higher in single center studies.

The difference between low and high volume centers have been reported for other cardiac procedures ([@b76-vhrm-4-1011]) and for AAA repair ([@b19-vhrm-4-1011]). In this report, there were no differences in baseline differences in AAA diameter or age, and slightly more ASA IV patients in EVAR in low volume centers. Balancing this is that high volume centers had more patients receiving EVAR with smoking history, hyperlipidemia and other comorbidities. This translates into similar outcomes in low volume and high volume centers, with the exception of chronic renal failure being higher in EVAR for high volume centers.

Studies that have patients, who are suitable for both EVAR and OSR should have results similar to RCTs because of similar anatomical suitability. Collectively, the total number of these patients is the same as an RCT (larger than DREAM, smaller than EVAR 1). Mortality difference and cardiac, pulmonary and renal outcomes are similar to the RCTs. One key difference is the total length of hospital stay, which is much higher in EVAR in the nRCT suitable patients. This suggests that the differences in ASA III or IV lead to differences in OR times, ICU stay and hospital stay.

The RCTs and most nRCTs have a mixed population, with high risk and low risk patients. In this report, 8 studies that looked exclusively at high-risk patients were identified, These high risk patients incurred a lower rate of cardiac and pulmonary problems in EVAR than OSR. This suggests a significant benefit for high risk patients in terms of reduced systemic outcomes even when they are at a higher relative risk.

Long term data was analyzed to compare EVAR versus OSR for long term mortality. No statistical difference was found for up to 36 months. Almost all recent evidence has reported no significant difference in long term mortality ([@b36-vhrm-4-1011]; [@b54-vhrm-4-1011]). Differences that existed earlier ([@b100-vhrm-4-1011]) no longer exist.

Outcomes reported for EVAR have been improving over time and there are a number of reasons for this. First, there has been improvements in outcomes for EVAR surgical procedures through an evolving experience curve ([@b42-vhrm-4-1011]) preselecting suitable patients that would benefit from EVAR, or adjusting the device and perioperative adjuvant procedures to reduce later complications such as endoleaks and limb ischemia. Second, there have been improvements in the EVAR device almost eliminating type 3 or 4 endoleaks (device failures). Third, there has been an increased tendency to have lower risk patients receive EVAR ([@b4-vhrm-4-1011]). In comparison, other studies have reported improving outcomes for patients that receive OSR ([@b14-vhrm-4-1011]). This is the first study that demonstrates that the mortality risk difference is only slightly falling with time. This is supported by earlier comparative meta-analysis and recent comparative meta-analysis.

EVAR highlights the problem of performing a fixed point in time meta-analysis of a procedure that is continually evolving and technologically improving over time.
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###### 

Difference in patient characteristics by study design and risk status

                      RCT                                                     nRCT                                                   Multi-center                                           Single center                                          Low volume                                             High volume                                            Suitable                                                High risk
  ------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------- -------------------------------------------------------
  Studies             4                                                       75                                                     16                                                     59                                                     31                                                     28                                                     5                                                       8
  \# EVAR patients    791                                                     16,407                                                 12,036                                                 4,371                                                  1,496                                                  2,875                                                  260                                                     332
  \# OSR patients     752                                                     41,238                                                 36,443                                                 4,795                                                  1,752                                                  3,043                                                  235                                                     352
                      WMD.                                                    WMD.                                                   WMD.                                                   WMD.                                                   WMD.                                                   WMD.                                                   WMD.                                                    WMD.
  Age                 −0.43                                                   −2.02                                                  −2.27                                                  −1.49                                                  −2.03                                                  −1.01                                                  −1.17                                                   −2.84
  AAA diameter (cm)   −0.04                                                   0.27                                                   0.15                                                   0.36                                                   0.24                                                   0.54                                                   −0.02                                                   0.16
                      Odds Ratio                                              Odds Ratio                                             Odds Ratio                                             Odds Ratio                                             Odds Ratio                                             Odds Ratio                                             Odds Ratio                                              Odds Ratio
  Male %              1.13                                                    **1.64[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.76[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.44[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.19[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.62[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.23                                                    **1.66[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**
  ASA I               0.82                                                    **0.20[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   n.a.                                                   **0.20[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.21[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   n.a.                                                   n.a.                                                    n.a.
  ASA II              1.21                                                    **0.72[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   n.a.                                                   **0.72[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.52[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.19                                                   **0.09[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    n.a.
  ASA III             1.14                                                    **1.33[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.01                                                   **1.33[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.06                                                   **1.53[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **2.93[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    **0.39[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**
  ASA IV              n.a.                                                    **1.49[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.04                                                   **2.38[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **3.87[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **2.13[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **12.34[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **10.80[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**
  Smoking history     1.17                                                    **1.19[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.20[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.22[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.83[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.57[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.81[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    **0.37[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**
  Hypertension        1.05                                                    **0.93[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.92[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.85[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.83[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **0.86[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.66[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    0.97
  Diabetes            0.79                                                    **1.28[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.22[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.42[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.18                                                   **1.58[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.15                                                    1.74
  Hyperlipidemia      0.93                                                    **1.22[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   0.97                                                   **1.61[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.29[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.80[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **2.14[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    n.a.
  Cardiac Disease     0.95                                                    **1.84[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **2.25[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.38[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.13                                                   **1.56[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.39[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    **1.39[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**
  CVD                 n.a.                                                    0.89                                                   **0.68[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.28[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   0.98                                                   **1.38[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   n.a.                                                    n.a.
  Pulmonary           **1.81 [\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.01                                                   **0.87[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.43[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.64[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.34[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.58[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**    1.19
  PVD                 n.a.                                                    **1.28[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.21[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.39[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   0.77                                                   **2.33[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   n.a.                                                    1.25
  Renal               0.77                                                    0.97                                                   **0.79[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   **1.27[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   1.13                                                   **1.31[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   0.72                                                    1.15
  Stroke              n.a.                                                    0.48                                                   **0.20[\*](#tfn1-vhrm-4-1011){ref-type="table-fn"}**   0.92                                                   n.a.                                                   0.72                                                   n.a.                                                    n.a.

**Notes:** \*statistically significant: p-value \<0.05. Both WMD and Odds Ratio were calculated with patient weights.

**Abbreviations:** n.a., not available; WMD, weighted mean difference; EVAR-OSR, Odds Ratio (EVAR/OSR).

###### 

Mortality and systemic complications

                                 RCT                                                     nRCT                                                    Multi-center                                             Single center                                           Low volume                                              High volume                                             Suitable                                                High risk
  ------------------------------ ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  **Mortality**                  **0.336[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.429[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.437[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.539[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.508[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.555[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.797                                                   0.517
  **Cardiac**                                                                                                                                                                                                                                                                                                                                                                                                                             
    Myocardial infarction        0.655                                                   **0.401[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.250[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.463[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.178                                                   **0.486[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Congestive heart failure     0.159                                                   **0.551[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                       0.622                                                   --                                                      0.736                                                   --                                                      --
    Arryhthmia                   --                                                      **0.198[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.391                                                    0.216                                                   **0.107[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.262[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Angina                       --                                                      **0.047[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                       **0.051[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --                                                      --                                                      --
    Unspecified                  0.752                                                   **0.473[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.383[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.661[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.759                                                   **0.506[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.611                                                   **0.076[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**
  **Pulmonary**                                                                                                                                                                                                                                                                                                                                                                                                                           
    Failure                      --                                                      **0.268[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.226[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.263[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.267[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.268[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Edema                        --                                                      0.375                                                   --                                                       1.233                                                   --                                                                                                              --                                                      --
    Pneumonia                    --                                                      **0.201[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.242[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.164[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.270                                                   **0.160[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      0.306
    Pulmonary embolism           --                                                      **0.127[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.657                                                    **0.050[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **0.057[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Unspecified                  --                                                      **0.219[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.204[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.255[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.219[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.282[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.105[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.075[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**
    Major                        **0.246[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.288[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.427[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.126[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **0.168[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Moderate                     **0.265[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --                                                       --                                                      --                                                      --                                                      --                                                      --
  **Renal**                                                                                                                                                                                                                                                                                                                                                                                                                               
    Permanent failure            --                                                      **0.290[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.102[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    0.634                                                   0.000                                                   **3.098[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Temporary failure            1.018                                                   **0.553[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.258[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    0.717                                                   0.479                                                   0.859                                                   --                                                      0.322
    Unspecified                  --                                                      **0.396[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   **0.391[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**    **0.422[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.593                                                   **0.368[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.483                                                   0.314
  **Stroke and ischemia**                                                                                                                                                                                                                                                                                                                                                                                                                 
    Stroke                       --                                                      0.476                                                   **0.196 [\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.916                                                   --                                                      0.715                                                   --                                                      --
    Transient ischemia Attacks   **0.321[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --                                                       --                                                      --                                                      --                                                      --                                                      --
    Bowel/colon ischemia         2.047                                                   **0.302[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.197                                                    **0.328[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   0.871                                                   **0.238[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Limb ischemia                --                                                      **1.866[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                       **2.134[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   2.711                                                   **2.032[\*](#tfn3-vhrm-4-1011){ref-type="table-fn"}**   --                                                      --
    Spinal ischemia              0.506                                                   --                                                      --                                                       0                                                       --                                                      --                                                      --                                                      --
    Other ischemia               --                                                      0.511                                                   --                                                       0                                                       --                                                      --                                                      --                                                      0.822

**Notes:** \*statistically significant: p-value \<0.05. -- : not available,

WMD (weighted mean difference) (EVAR-OSR). Odds ratio (EVAR/OSR). Both WMD and odds ratio were calculated with patient weights.

###### 

Surgical outcomes

                           RCT                                                     nRCT                                                    Multi-center                                            Single center                                           Low volume                                              High volume                                             Suitable                                                 High risk
  ------------------------ ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------
  Operating time (hours)   −**0.30[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −0.85                                                   −**1.03[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −0.80                                                   −0.40                                                   −**1.08[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −2.70                                                    −0.39
  Blood loss (mL)          −**1243[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1285[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1216[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1306[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1413[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1178[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**1629[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**    −**2261[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**
  Intensive care (days)    −4.81                                                   −2.24                                                   −**2.12[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −2.32                                                   −2.07                                                   −2.22                                                   −**0.80[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**    −**1.94[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**
  Length of stay (days)    −**5.55[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**5.54[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**5.79[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**5.36[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**5.97[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**4.93[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**12.30[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**   −**6.80[\*](#tfn4-vhrm-4-1011){ref-type="table-fn"}**

**Notes:** \*statistically significant: p-value \<0.05. Both WMD and odds ratio were calculated with patient weights.

**Abbreviations:** WMD, weighted mean difference; EVAR-OSR, odds ratio (EVAR/OSR).

###### 

Local/vascular complications

                                RCT                                                     nRCT                                                    Multi-center                                            Single center                                           Low volume                                              High volume                                             Suitable   High risk
  ----------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ---------- -------------------------------------------------------
  Graft infection               0.506                                                   4.646                                                   --                                                      3.518                                                   --                                                      2.458                                                   --         --
  Graft thrombosis              --                                                      **3.088[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   2.242                                                   2.981                                                   --                                                      **3.051[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --         --
  Aortenteric fistula           --                                                      --                                                      --                                                      --                                                      --                                                      --                                                      --         --
  Arterial/graft obstruction    --                                                      **2.853[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **2.890[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   1.566                                                   **8.952[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   2.635      --
  Groin minor                   --                                                      **2.869[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **3.035[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **3.777[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   1.735                                                   2.269      --
  Groin/wound infection         --                                                      0.871                                                   **0.491[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   1.197                                                   **2.16[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**    0.977                                                   0.738      --
  Hemorrhage -- major           **0.165[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.297[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.251[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.288[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.305[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.269[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   1.747      --
  Hemorrhage -- moderate        --                                                      **0.421[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **0.421[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   **0.344[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   0.577                                                   --         **0.177[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**
  Pseudoaneurysm -- abdominal   --                                                      **0.151[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      0.209                                                   --                                                      --                                                      --         --
  Thromboembolism -- major      2.047                                                   **0.229[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **0.249[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   0.521                                                   **0.203[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --         --
  Thromboembolism -- moderate   --                                                      **2.435[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --                                                      **2.297[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   1.613                                                   **7.200[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   --         --
  Wound major                   1.018                                                   0.570                                                   **0.380[\*](#tfn6-vhrm-4-1011){ref-type="table-fn"}**   0.230                                                   --                                                      0.232                                                   --         --

**Notes:** \*statistically significant: p-value \<0.05. Both WMD and odds ratio were calculated with patient weights.

**Abbreviations:** WMD, weighted mean difference; EVAR-OSR, odds ratio (EVAR/OSR).

###### 

EVAR outcomes

  Studies                RCT 4   nRCT 75   Multi-center 16   Single center 59   Low volume 31   High volume 28   Suitable 5   High risk 8
  ---------------------- ------- --------- ----------------- ------------------ --------------- ---------------- ------------ -------------
  Endoleaks              \%      \%        \%                \%                 \%              \%               \%           \%
    type1                0       6.27      4.37              7.89               8.47            7.51             15.00        2.22
    type2                5.0     10.57     8.47              12.11              13.51           11.4             5.00         26.67
    type3                0       0.69      0.67              0.72               0.60            0.79             0            1.11
    type4                0       1.07      2.14              0                  0               0                0            0
  Conversion             1.81    1.49      1.95              0.98               1.09            0.94             0.38         0.36
  Graft obstruction      n.a.    1.08      0                 1.59               5.58            0                14.46        0
  Graft kinks or folds   n.a.    0.53      0.64              0.45               1.35            0                0            0
  Graft migration        n.a.    0.61      0.35              0.86               2.02            0.17             0            8.33

###### 

Endoleaks and limb ischemia

  Outcome                    Meta-analysis % (95% CI)   Meta-regression trend % (P-value)
  -------------------------- -------------------------- ---------------------------------------------------------------
  Endoleak                                              
    Type 1                   6.77% (3.26% to 10.27%)    −0.76% (P = 0.39)
    Type 2                   9.78% (6.76% to 12.79%)    −0.47% (P = 0.59)[\*](#tfn9-vhrm-4-1011){ref-type="table-fn"}
    Type 3                   0.68% (0.43% to 0.94%)     +0.17% (P = 0.01)
    Type 4                   0.33% (0.12% to 0.54%)     −0.22% (P \< 0.01)
  Limb ischemia (EVAR-OSR)   0.95% (0.94% to 0.96%)     −0.02% (P \< 0.01)

**Notes:** Coefficient on time trend in meta-regression;

\*: one outlier with 100% rate of Type 2 Endoleak was removed from analysis.
